Intraventricular immunovirotherapy; a translational step forward

Oncolytic virotherapy with intratumoral engineered type-1 herpes simplex virus (HSV) has been proven safe with promising efficacy in recent clinical trials for treatment of both pediatric and adult high-grade glioma. However, this approach excludes patients with tumors in surgically inaccessible and...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2023-01, Vol.14 (1), p.40
Main Authors: Bernstock, Joshua D, Blitz, Sarah, Kang, Kyung-Don, Friedman, Gregory K
Format: Article
Language:English
Subjects:
Adult
Animals
Cerebellar Neoplasms
Child
Glioma
Humans
Mice
Oncolytic Virotherapy - methods
Oncolytic Viruses - genetics
Simplexvirus
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oncolytic virotherapy with intratumoral engineered type-1 herpes simplex virus (HSV) has been proven safe with promising efficacy in recent clinical trials for treatment of both pediatric and adult high-grade glioma. However, this approach excludes patients with tumors in surgically inaccessible and/or eloquent brain regions. Current delivery methods are also unable to access/treat those patients with metastatic disease in the spinal cord and/or leptomeningeal disease. A recent preclinical study has paved the way for clinical translation of intraventricular administration of oHSV by identifying and mitigating the toxicity associated with this route for therapeutic benefit in murine models of disseminated medulloblastoma. This work may ultimately allow for targeting of intractable disease and provides a feasible option for the repetitive dosing of clinically relevant immunovirotherapy, G207.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.28343